Stifel's lone Hold against a sea of Buy ratings is a notable contrarian call, but the bearish case is reinforced by heavy insider selling and a wave of downward EPS revisions. The extreme 73% short interest creates a high-risk, high-reward setup where any positive catalyst could trigger a sharp squeeze, but the fundamental signals currently favor the bears.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Oct 1 $20.89entry
- T+1 · 7w ago +0.05%α −0.69% · $20.90
- T+5 · 6w ago −7.56%α −8.86% · $19.31
- T+20 · 19d ago −12.59%α −13.29% · $18.26
- T+32 · todayOpen
- T+60 · in 6w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and a $24 price target on October 1, 2026. The firm's 54% accuracy on 2,973 calls and average return of 4.5% place it in the middle tier among analysts covering the stock. The consensus is overwhelmingly bullish, with 19 of 20 analysts rating IMNM a Buy or Strong Buy, and only one Hold (Stifel). The mean price target of $36 implies 67.4% upside from the current $21.51, while Stifel's $24 target sits well below the consensus range of $30–$40. Over the past 30 days, EPS estimates have seen 10 downward revisions for the current fiscal year versus zero upward revisions, signaling deteriorating expectations. Insider selling has been notable, with CFO Isaac Barchas selling over $2.6M in August 2026 and CEO Jack Higgins selling $334k in September. Short interest stands at 73.1% of float, an extremely elevated level that could amplify any positive catalyst. The next earnings report is due November 16, 2026, roughly six weeks out. Stifel's cautious initiation stands as a contrarian call against a heavily bullish consensus, but the firm's middling track record and the bearish insider and estimate revision signals temper the significance.
Impact Score
Consensus & Targets
The consensus is 95% Buy/Strong Buy: 5 Strong Buy, 14 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 20 analysts. Stifel's Hold is the only non-bullish rating, making this a clear contrarian call.
Current price: $21.51. Consensus mean PT: $36, median: $36, high: $40, low: $30. Implied upside to mean: 67.4%. Stifel's $24 PT is the lowest on the street, 33% below the mean and 20% below the prior low of $30.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-01 | Stifel | initiate | Hold | $24.00 |
| 2026-09-21 | Alliance Global Partners | initiate | Buy | $32.00 |
| 2026-09-10 | HC Wainwright & Co. | reiterate | Buy | $40.00 |
| 2026-08-12 | Truist Securities | maintain | Buy | $38.00 |
| 2026-08-12 | Wedbush | maintain | Outperform | $35.00 |
| 2026-07-21 | Wedbush | reiterate | Outperform | $31.00 |
| 2026-06-12 | Wedbush | reiterate | Outperform | $31.00 |
| 2026-05-28 | Truist Securities | maintain | Buy | $37.00 |
| 2026-05-28 | Barclays | initiate | Overweight | $36.00 |
| 2026-05-15 | Leerink Partners | maintain | Outperform | $33.00 |
Over the past 30 days, there have been 2 upgrades and 0 downgrades. However, EPS estimate revisions are heavily negative: 10 downward revisions for the current fiscal year (0y) and 7 for the current quarter (0q) versus 3 upward revisions for 0q. The trend is clearly deteriorating.
Firm Track Record: Stifel
Stifel accuracy: 54% on 2973 calls | avg return: 4.5%
Industry benchmark: mean 51% ± 10%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| JP Morgan | 100% | 2/2 | 32.2% | top tier |
| Stephens & Co. | 67% | 2/3 | 3.3% | top tier |
| Evercore ISI Group | 50% | 1/2 | 33.3% | below average |
| Lake Street | 50% | 1/2 | 7.7% | below average |
| Guggenheim | 50% | 2/4 | 11.8% | below average |
| Piper Sandler | 33% | 1/3 | -6.5% | below average |
| Wedbush | 25% | 1/4 | -19% | below average |
Stifel has a 54% accuracy rate on 2,973 scored calls with a 4.5% average return, placing it in the middle tier. Among firms covering IMNM, JP Morgan leads with 100% accuracy (2/2) and a 32.2% avg return, while Wedbush is weakest at 25% (1/4) with a -19% avg return.
Earnings Estimates
Next earnings: Nov 16, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1y | $-2.43 | $-2.90 to $-1.85 | $54.3M | ↑1 ↓0 |
| 0q | $-0.59 | $-0.71 to $-0.41 | $153.8K | ↑3 ↓0 |
| 0y | $-2.29 | $-2.56 to $-2.02 | $307.7K | ↑0 ↓0 |
| +1q | $-0.61 | $-0.75 to $-0.38 | $153.8K | ↑2 ↓0 |
Cross-Platform Signals
Insider selling is a strong bearish signal: CFO Isaac Barchas sold over $2.6M in four August 2026 trades, and CEO Jack Higgins sold $334k in September. No insider buys are recorded. Institutional activity is mixed: Citadel doubled its position (+179.4%) and Dimensional Fund Advisors added 10x, while JP Morgan trimmed 33.5% and T. Rowe Price cut 38%. Short interest is extreme at 73.1% of float, indicating heavy bearish positioning that could fuel a squeeze on positive news. No congressional trades are reported.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Viewing Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers